Business
Oculis to Participate in Upcoming November Investor Conferences
ZUG, Switzerland, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on
About this update from Oculis Holding Ag
[{"type":"text","content":"ZUG, Switzerland, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, announced today that Oculis’ management will participate in upcoming investor conferences in November. Oculis is pleased to present updates of its innovative, highly differentiated, late-stage portfolio as it enters a pivotal phase in its transformation into a leader in neuro-ophthalmology and ophthalmology. Key highlights include: Privosegtor (PIONEER program) advancement into registrational trials for acute optic neuritis and non-arteritic anterior ischemic optic neuropathy (NAION), following a positive FDA meeting; OCS-01 (DIAMOND registrational trials) topline results for diabetic macular edema expected in Q2 2026; and Licaminlimab (PREDICT-1 registrational trial) in DED anticipated soon, marking the first genotype-based development program to drive precision medicine. With a strong balance sheet and robust pipeline, Oculis is well-positioned to deliver 6 pivotal readouts with the current funding, to fulfil its mission to save sight and improve eye care with groundbreaking treatments. Guggenheim Securities 2nd Annual Healthcare Innovation ConferenceNovember 10-12; Boston, U.S.Fireside chat with Riad Sherif, M.D., Chief Executive Officer, on November 11th at 2:30 pm ET. Webcast link: Register here. Stifel Healthcare ConferenceNovember 11-13; New York, U.S.Fireside chat with Riad Sherif, M.D., Chief Executive Officer, on November 12th at 2:00 pm ET. Webcast link: Register here. LifeSci Capital and Sofinnova Partners Growth & Innovation SummitNovember 17; London, U.K.Oculis management will participate in one-to-one meetings. ICR Healthcare and Sponsors 13th Annual Healthcare ConferenceNovember 17; London, U.K.Riad Sherif, M.D., Chief Executive Officer, will participate in a panel discussion, entitled ‘Brave New World,’ at 1:50 pm GMT. The company will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative at the sponsoring institutions to request meetings. Webcast links, when available, will be posted to the Oculis website on the Events & Presentation page under the Investors & Media section. Abo...